Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 2, pp 243–252 | Cite as

Adverse drug reactions associated with asthma medications in children: systematic review of clinical trials

  • Lise AagaardEmail author
  • Ebba Holme Hansen
Review Article

Abstract

Background Respiratory medications are frequently prescribed for use in children. Several studies have reported information on the safety of asthma medications in clinical studies in adults, but information about safety in children is scarce. Objective To review published clinical trials on the occurrence and characteristics of adverse drug reactions (ADRs) in children, reported for asthma medications licensed for paediatric use. Methods We systematically reviewed the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. PubMed, Embase, Cochrane Library, PsycINFO, IPA, and CINAHLs databases were searched from origin until July 2013 for studies reporting ADRs for beta2-receptor agonists, inhaled corticosteroids, leukotriene receptor antagonists and combination products in children from birth to age 17. Information on ADR reporting rates, age and gender, type and seriousness of ADRs, design, setting, observation period, type of assessors, and funding sources was extracted from the articles. Results Literature searches resulted in 162 potential relevant articles. However only 12 of these studies were included in this review as they reported information about ADR rates from use of salmeterol, formoterol, fluticasone, montelukast, zafirlukast and budesonide/formoterol in children. The total population was approximately 3,000 children; the majority was 6- to 11-year-olds and two thirds of these were boys. The observation period varied from 1 to 22 months. The most frequently reported ADRs were exacerbation of asthma, respiratory tract infection, cough, fever and headache. Only few ADRs were rated as being serious, however a number of children dropped out of the clinical trials due to serious ADRs, and, therefore, the real number of serious ADRs is probably higher. Conclusions Few clinical trials reporting ADRs from use of asthma medications in children were identified in the literature. These studies reported only a few types of ADRs, the majority being non-serious.

Keywords

Adverse drug reactions Asthma Children Pharmacovigilance Pediatric indication 

Notes

Acknowledgments

We thank Dr. T.W. de Vries, Paediatric Department, Medisch Centrum Leeuwarden, Netherlands, for commenting on previous drafts of this manuscript. We also thank MSc (pharm) Malene Hammer Krag for assistance with quality assurance of data extractions. Furthermore we also thank the information specialists at the National Library of Denmark and Copenhagen University Library for assistance with the literature searches.

Funding

No sources of funding were used to assist in the preparation of this study.

Conflicts of interest

None.

Supplementary material

11096_2014_9924_MOESM1_ESM.docx (65 kb)
Supplementary material 1 (DOCX 64 kb)

References

  1. 1.
    Thrane N, Sørensen HT. A one-year population-based study of drug prescriptions for Danish children. Acta Paediatr. 1999;88:1131–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Grover C, Armour C, Asperen PP, Moles R, Saini B. Medication use in children with asthma: not a child size problem. J Asthma. 2011;48:1085–103.PubMedCrossRefGoogle Scholar
  3. 3.
    Arellano FM, Arana A, Wentworth CE, Vidaurre CF, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. Pediatr Allergy Immunol. 2011;22:469–76.PubMedCrossRefGoogle Scholar
  4. 4.
    Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf. 2010;33(4):327–39.PubMedCrossRefGoogle Scholar
  5. 5.
    Star K, Noren N, Nordin K, Edwards RI. Suspected adverse drug reactions reported for children worldwide. An explanatory study using VigiBase. Drug Saf. 2011;34:415–28.PubMedCrossRefGoogle Scholar
  6. 6.
    De Vries TW, de Langen-Wouterse JJ, van Puijenbroek E, Duiverman EJ, den Berg LTW. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol. 2006;62:343–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6(6):e1000097. doi: 10.1371/journal.pmed1000097.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Von Berg A, De Blic J, La Rosa M, Kaad PH, Moorat A. A comparison of regular salmeterol vs “as required” salbutamol therapy in asthmatic children. Respir Med. 1998;92:292–9.CrossRefGoogle Scholar
  9. 9.
    Von Berg A, Papageorgiou F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbohaler in children. Int J Clin Pract. 2003;57:852–6.Google Scholar
  10. 10.
    Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: double-blind trial in asthmatic children using powder devices at a dosage of 400 mg/day. Eur Respir J. 1996;9:2263–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6-14-year-old children. JAMA. 1998;279:1181–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Pearlman DS, Lampl KL, Dowling PJ, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther. 2000;22:732–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥6 years. Clin Exp Allergy. 2000;31:77–87.CrossRefGoogle Scholar
  14. 14.
    Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist for the treatment of persistent asthma in children aged 2 to 5 years. Pediatr. 2001;108:e48.CrossRefGoogle Scholar
  15. 15.
    Maspero JF, Duenas-Meza E, Volovitz B, Daza CP, Kosa L, Vrijens F, et al. Oral montelukast versus inhaled beclomethasone in 6-11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction and adherence with therapy. Curr Med Res Opin. 2001;17:96–104.PubMedCrossRefGoogle Scholar
  16. 16.
    Bukstein DA, Bratton DL, Firriolo KM, Estojak J, Bird SR, Hustad CM, et al. Evaluation of parenteral preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma. 2003;40:475–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast compared with fluticasone for control of asthma among 6-to 14-Year-old patients with mild asthma: the MOSAIC study. Pediatr. 2005;116:360–9.CrossRefGoogle Scholar
  18. 18.
    Van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability and exploratory efficacy of montelukast in 6-to-24-month-old patients with asthma. Curr Med Res Opin. 2005;21:971–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulm. 2002;34:342–50.CrossRefGoogle Scholar
  20. 20.
    Duggan EM, Sturley J, Fitzgerald AP, Perry IJ, Hourihane JO. The 2002–2007 trends of prevalence of asthma, allergic rhinitis and eczema in Irish schoolchildren. Pediatr Allergy Immunol. 2012;23:464–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Beasley R, Holt S, Fabian D, Masoli M. Global burden of asthma. Global initiative for asthma (GINA). www.ginasthma.org/. Last accessed 4 July 2013.
  22. 22.
    National Heart Lung and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3). http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Last accessed 4 July 2013.
  23. 23.
    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs, and NSAIDs. BMC Clin Pharmacol. 2009;9:4.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Gøtzsche P, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006;295:1645–6.PubMedGoogle Scholar
  26. 26.
    De Vries T, Van Roon EN. Low quality of reporting adverse drug reactions in paediatric randomised controlled clinical trials. Arch Dis Child. 2010;95:1023–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Rogers L, Reibman J. Stepping down asthma treatment: how and when. Curr Opin Pulm Med. 2012;18:70–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Chan AW, Hrobjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;26:2457–65.CrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  1. 1.Faculty of Health Sciences, Institute of Public HealthUniversity of Southern DenmarkOdense CDenmark
  2. 2.Section for Social and Clinical Pharmacy, Department of Pharmacy, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations